FinancialContent is the trusted provider of stock market information to the media industry.
More NewsRead More
Galectin Therapeutics Begins Phase 2a Psoriasis Study With GR-MD-02
September 24, 2015
Galectin Therapeutics to Present at 2015 Ladenburg Thalmann Healthcare Conference
September 22, 2015
Galectin Therapeutics Announces Start of Phase 2 Clinical Trial With GR-MD-02 in NASH With Advanced Fibrosis
September 16, 2015
Galectin Therapeutics to Participate in Three Investment Conferences in September
September 08, 2015
Galectin Therapeutics Receives U.S. Patent Notice of Allowance for Use of Pectin Compounds to Reduce Fibrosis in Multiple Diseases
August 13, 2015
Galectin Therapeutics Provides Phase 2 NASH Program Update and Reports Second Quarter 2015 Financial Results
August 10, 2015
Exalenz Bioscience Announces Collaboration with Galectin Therapeutics to use BreathID® to Monitor Patients with Cirrhosis Associated with NASH
August 03, 2015
from PR Newswire
Galectin Therapeutics Inc. Appoints Adam E. Allgood, Pharm.D., R.Ph., as Executive Director of Clinical Development
July 15, 2015
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here